

## References

1. Belenkov YuN. *Serdce – Heart* 2006;5:1–3 (in Russ).
2. Belenkov YuN, Mareev VYu. *Insayt poligrafik*, 2002. 86 p (in Russ).
3. Aksnes TA, Flaa A, Strand A, Kjeldsen SE. Prevention of new-onset atrial fibrillation and its predictors with angiotensin-II-receptor blockers in the treatment of hypertension and heart failure. *J. Hypertens* 2007;25:15–23.
4. Alcocer L. Clinical acceptability of ACE inhibitor therapy in mild to moderate hypertension, a comparison between perindopril and enalapril. *Cardiovasc Drugs Ther* 1995;9:431–436.
5. Alderman M.H. Plasma renin activity and coronary heart disease: are they related. *Curr. Opin. Nephrol. Hypertens* 1995;4:201–203.
6. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Yu, Anderson C, Belhani A, Forette F, Rajkumar Ch, Thijs L, Banya W, Bulpitt CJ, M.D. for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. *N. Engl. J. Med* 2008;358:1887–1889.
7. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: The Rotterdam Study. *Circulation* 1997;96:1432–1437.
8. Brunner H.R. Essential hypertension: renin and aldosterone, heart attack and stroke. *N Engl J Med* 1972;286:441–449.
9. Cocroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. *Nephron* 1976;16:31–41.
10. Cuspidi C, Ambrosioni E, Mancia G, Pessina AC, Trimarco B, Zanchetti A; APROS Investigators. Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the Assessment of Prognostic Risk Observational Survey. *J Hypertens* 2002;20:1307–1314.
11. Cuspidi C, Muiesan ML, Valagussa L, Salvetti M, Di Biagio C, Agabiti-Rosei E, Magnani B, Zanchetti A; CATCH investigators. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the Candesartan Assessment in the Treatment on Cardiac Hypertrophy (CATCH) study. *J Hypertens* 2002;20:2293–2300.
12. Cuspidi C, Meani S, Valerio C, Fusi V, Catini E, Sala C, Zanchetti A. Ambulatory blood pressure, target organ damage and left atrial size in never-treated essential hypertensive individuals. *J Hypertens* 2005;23:1589–1595.
13. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. *Lancet* 2006;368:581–588.
14. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet* 2002;359:995–1003.

15. Devereux RB, Wachtell K, Gerds E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris K, Aurup P, Dahlöf B. Prognostic significance of left ventricular mass change during treatment of hypertension. *JAMA* 2004;292:2350–2356.
16. Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, Michelson EL, McMurray JJ, Olsson L, Rouleau JL, Young JB, Olofsson B, Puu M, Yusuf S; CHARM Investigators. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. *Am Heart J* 2006;152:82–92.
17. ESC Guidelines for the Management of atrial fibrillation. *Eur Heart J* 2010, doi:10. 1093 (2010 Version) eurheartj/egh 278.
18. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ; Comparative Risk Assessment Collaborating Group. Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. *Lancet* 2002;360:1347–1360.
19. Fogari R, Mugellini A, Destro M, Corradi L, Zoppi A, Fogari E, Rinaldi A. Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. *J Cardiovasc Pharmacol* 2006;47:46–50.
20. Gerds E, Wachtell K, Omvik P, Otterstad JE, Oikarinen L, Boman K, Dahlöf B, Devereux RB. Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for end-point reduction in hypertension trial. *Hypertension* 2007;49:311–316.
21. Goette A, Staack T, Röcken C, Arndt M, Geller JC, Huth C, Ansorge S, Klein HU, Lendeckel U. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. *J Am Coll Cardiol* 2000;35(6):1669–1677.
22. Guidelines Committee. 2003 European Society of Hypertension – European Society of Cardiology Guidelines for the management of arterial hypertension. *J Hypertens* 2003;21:1011–1053.
23. Hallan S, Asberg A, Lindberg M, Johnsen H. Validation of the Modification of Diet in Renal Disease formula for estimating GFR with special emphasis on calibration of the serum creatinine assay. *Am J Kidney Dis* 2004;44:84–93.
24. Hankey GJ. Preventable stroke and stroke prevention. *J Tromb Haemost* 2005;3:1638–1645.
25. Healy J.S., Baranchuk A., Cristal E, Morillo CA, Garfinkle M, Salim Yusuf, Connolly SJ. Prevention on atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. *J Am Coll Cardiol* 2005;45:1832–1839.
26. Jamerson K, Neber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ, for the ACCOMPLISH. Trial Investigators Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. *N Engl J Med* 2008;359:2417–2422.
27. Jibrini M.B., Molnar J., Arora R.R. Prevention of the renin-angiotensin system: a systematic review and meta-analysis. *Am J Ther* 2008;15:36–43.

28. Jong P, Yusuf S, Rousseau MF, Ahn SA, Bangdiwala SI. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. *Lancet* 2003;361:1843–1848.
29. Kannel W.B. Blood pressure as a cardiovascular risk factor: prevention and treatment. *JAMA* 1996;275:1571–1576.
30. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis and predisposing conditions for atrial fibrillation: population based estimates. *Am J Cardiol* 1998;82:2N-9N.
31. Kizer JR, Bella JN, Palmieri V, Liu JE, Best LG, Lee ET, Roman MJ, Devereux RB. Left atrial diameter as an independent predictor of first clinical cardiovascular events in middle-aged and elderly adults: the Strong Heart Study (SHS). *Amer Heart J* 2006;151:412–418.
32. Komatsu T, Ozawa M, Tachibana H, Sato Y, Orii M, Kunugida F, Nakamura M. Combination therapy with amiodarone and enalapril in patients with paroxysmal atrial fibrillation prevents the development of structural atria remodeling. *Int Heart J* 2008;49:435–447.
33. Lawes CM. Global burden of blood-pressure-related disease. *Lancet* 2008;371:1513–1518.
34. Laukkanen JA, Kurl S, Eränen J, Huttunen M, Salonen JT. Left atrium size and the risk of cardiovascular death in middle-aged men. *Arch. Intern. Med* 2005;165:1788–1793.
35. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. *JAMA* 1996;275:1557–1562.
36. Levy D, Garisson RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. *N Engl J Med* 1990;322:1561–1566.
37. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. *Chest* 2010;137:163–272.
38. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J. Blood pressure, stroke and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. *Lancet* 1990;335:765–774.
39. Madrid AH, Bueno MG, Rebollo JM. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. *Circulation* 2002;106:331–336.
40. Maggioni AP, Latini R, Carson PE, Singh SN, Barlera S, Glazer R, Masson S, Cerè E, Tognoni G, Cohn JN; Val-HeFT Investigators. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). *Am Heart J* 2005;149:548–557.
41. Mancia G, Facchetti R, Bombelli M, Polo Friz H, Grassi G, Giannattasio C, Sega R. Relationship of office, home and ambulatory blood pressure to blood glucose and lipid variables in the PAMELA population. *Hypertension* 2005;45:1072–1077.

42. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens* 2007;25:1105–1187.
43. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, Cifkova R, Clément D, Coca A, Dominiczak A, Erdine S, Fagard R, Farsang C, Grassi G, Haller H, Heagerty A, Kjeldsen SE, Kiowski W, Mallion JM, Manolis A, Narkiewicz K, Nilsson P, Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L, Schmieder RE, Struijker-Boudier HA, van Zwieten PA, Viigimaa M, Zanchetti A; European Society of Hypertension. Reappraised of European guidelines of hypertension management: a European Society of Hypertension Task Force document. *J Hypertens* 2009;27:2121–2158.
44. Neal B, MacMahon S, Chapman N. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. *Lancet* 2000;356:1955–1964.
45. Okin PM, Wachtell K, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Julius S, Lindholm LH, Nieminen MS, Edelman JM, Hille DA, Dahlöf B. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. *JAMA* 2006;296:1242–1248.
46. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman J, Krause S, Burns D, Williams GH. Effects of eplerenone, enalapril and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. *Circulation* 2003;108:1831–1838.
47. Savelieva I, Camm AJ. Is there any hope for angiotensin-converting enzyme inhibitors in atrial fibrillation? *Am Heart J* 2007;154:403–406.
48. Schmieder RE, Kjeldsen SE, Julius S, McInnes GT, Zanchetti A, Hua TA; VALUE Trial Group. Reduced incidence of new onset atrial fibrillation with angiotensin II receptor blockade: the VALUE-trial. *J Hypertens* 2006;24:3.
49. Schneider MP, Hua TA, Böhm M, Wachtell K, Kjeldsen SE, Schmieder RE. Prevention of Atrial fibrillation by renin-angiotensin system inhibition a meta-analysis. *J Am Coll Cardiol* 2010;55:2299–2307.
50. Sica DA. EUROPA: has anything new been learned with angiotensin-converting enzyme inhibitors? *J Clin Hypertens* 2004;6:91–95.

51. Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A, Radzik D, Aliot EM, Hohnloser SH; EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. *N Engl J Med* 2007;357:987–999.
52. Staessen JA, Gasowski J, Wang JG, Thijs L, Den Hond E, Boissel JP, Coope J, Ekblom T, Gueyffier F, Liu L, Kerlikowske K, Pocock S, Fagard RH. Risk of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. *Lancet* 2000;355:865–872.
53. The EUROpean Trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind placebo-controlled, multicentre trial (The EUROPA study). *Lancet* 2003;362:782–788.
54. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. *N Engl J Med* 2000;342:145–153.
55. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. *Lancet* 2000;355:253–259.
56. The PEACE Investigators. Angiotensin converting enzyme inhibition in stable coronary artery disease. *N Engl J Med* 2004;354:2058–2068.
57. Tsang TS, Barnes ME, Gersh BJ, Bailey KR, Seward JB. Risk for atrial fibrillation and congestive heart failure in patients  $\geq 65$  years of age with abnormal left ventricular diastolic relaxation. *Am J Cardiol* 2004;93:54–58.
58. Verdecchia P, Reboldi G, Gattobigio R, Bentivoglio M, Borgioni C, Angeli F, Carluccio E, Sardone MG, Porcellati C. Atrial fibrillation in hypertension: predictors and outcome. *Hypertension* 2003;41:218–223.
59. Ueng KC, Tsai TP, Yu WC, Tsai CF, Lin MC, Chan KC, Chen CY, Wu DJ, Lin CS, Chen SA. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. *Eur Heart J* 2003;24:2090–2098.
60. Verdecchia P, Reboldi G, Gattobigio R, Bentivoglio M, Borgioni C, Angeli F, Carluccio E, Sardone MG, Porcellati C. Atrial Fibrillation in hypertension: predictors and outcomes. *Hypertension* 2003;41:218–223.
61. Vermees E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, Guerra PG, Ducharme A. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies of Left Ventricular Dysfunction (SOLVD) trials. *Circulation* 2003;107:2926–2931.
62. Wachtell K, Lehto M, Gerds E, Olsen MH, Hornestam B, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction Hypertension (LIFE) study. *J Am Coll Cardiol* 2005;45:712–719.
63. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. *Lancet* 2009;373:155–166.

64. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M; CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure lowering drugs on central aortic pressure and clinical outcomes. Principal results of the Conduit Artery Function Evaluation (CAFE) study. *Circulation* 2006;113:1213–1225.
65. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril or both in patients at high risk for vascular events. *N Engl J Med* 2008;358:1547–1559.